Not an actual patient.

APPROVED FOR ADULTS AND ADOLESCENTS* WITH ECZEMA (ATOPIC DERMATITIS)1

Itch relief like that

AS SOON AS 48 HOURS,
NEMLUVIO® relieves itch fast with skin healing that lasts—so you can have better days and nights1,2§

DISCOVER NEMLUVIO 

Aged 12 or older.1

PP-NRS response defined as a ≥4-point improvement from baseline. Data from Phase 3 clinical study (ARCADIA 1) post-hoc descriptive analysis of daily PP-NRS improvement; consistent results seen in ARCADIA 2. Significant Improvement was achieved at 48 hours (NEMLUVIO + TCS/TCI 9% vs 3% with placebo + TCS/TCI, P≤0.001).1,2

NEMLUVIO was proven to heal the rashes of eczema1

Explore real before and after photos of people who participated in the clinical trials using NEMLUVIO for 4 months.

Actual 26-year-old male patient at baseline with eczema (atopic deramtitis) on arms and chest. Actual 26-year-old male patient at baseline with eczema (atopic deramtitis) on arms and chest.
Actual 26-year-old male patient at Week 16 with improved eczema (atopic dermatitis) on chest and arms. Actual 26-year-old male patient at Week 16 with improved eczema (atopic dermatitis) on chest and arms.
 

BEFORE TREATMENT

AFTER TREATMENT

26-YEAR-OLD MALE.
Actual patient from 
clinical trial.
Individual results may vary.

26-YEAR-OLD MALE.
Actual patient from clinical trial.
Photo altered to remove identifying marks.
Individual results may vary.

Just 1 dose 
every 4 weeks1

Find support for injections, including a 
step-by-step video, to help you start 
using NEMLUVIO.

GET INJECTION SUPPORT  

Not an actual patient.

Not an actual patient.

Are you looking for less 
itch with lasting relief?1,2

Ask a dermatologist if NEMLUVIO could be right for you.

GPS (Galderma Patient Services) for NEMLUVIO™ (nemolizumab-­ilto) logo.
Image of the NEMLUVIO® (nemolizumab-ilto) Welcome Kit box.

Enroll for support

GPS for NEMLUVIO is by your side from the start. The GPS for NEMLUVIO support team is committed to providing one-on-one education and ongoing communications, including a Welcome Kit, to help you start and stay on track.

If you are already prescribed NEMLUVIO, you can complete enrollment over the phone at 1-855-NEMLUVIO or by clicking the link below.

If you are already prescribed NEMLUVIO, you can complete enrollment over the phone at 
1-855-NEMLUVIO or by clicking the link below.

COMPLETE ENROLLMENT 

44% of those using NEMLUVIO + TCS/TCI achieved significantly clearer skin at Week 16 vs 29% with placebo + TCS/TCI.1

As demonstrated by improvements in quality of life measurements, including the SD-NRS, for 38% of those using NEMLUVIO + TCS/TCI vs 20% using placebo + TCS/TCI.1

PP-NRS=Peak Pruritus Numerical Rating Scale; SD-NRS=Sleep Disturbance Numerical Rating Scale; TCI=topical calcineurin inhibitor; TCS=topical corticosteroid.

References: 1. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P. 2. Galderma Laboratories, L.P.; data on file.

Important Safety Information

Indications: NEMLUVIO® (nemolizumab-ilto) is a prescription medicine used:

  • to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis or AD) in combination with prescription therapies used on the skin (topical) when the eczema is not well controlled by topical therapies alone. It is not known if NEMLUVIO is safe and effective in children with atopic dermatitis under 12 years of age.
  • to treat adults with prurigo nodularis. It is not known if NEMLUVIO is safe and effective in children with prurigo nodularis under 18 years of age.

Do not take NEMLUVIO if you are allergic to nemolizumab-ilto or to any ingredients in NEMLUVIO. Before taking NEMLUVIO, tell your healthcare provider about all of your medical conditions, including if you:

  • are scheduled to receive any vaccination. You should not receive a live vaccine right before or during treatment with NEMLUVIO.
  • are pregnant or plan to become pregnant. It is not known whether NEMLUVIO will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known whether NEMLUVIO passes into your breast milk and if it can harm your baby.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

NEMLUVIO may cause serious side effects, including: allergic reactions (hypersensitivity). Stop using NEMLUVIO and tell your healthcare provider or get emergency help right away if you get any of the following symptoms:

  • Breathing problems or wheezing
  • Swelling of the face, lips, mouth, tongue, or throat
  • Fainting, dizziness, feeling lightheaded
  • Fast pulse
  • Swollen lymph nodes
  • Joint pain
  • Fever
  • Skin rash (red or rough skin)
  • Nausea or vomiting
  • General ill feeling
  • Cramps in your stomach area

The most common side effects of NEMLUVIO include:

  • Eczema: headache, joint pain, hives (itchy red rash or wheals), and muscle aches
  • Prurigo Nodularis: headache and skin rashes: atopic dermatitis (a type of eczema), eczema, and eczema nummular (scattered circular patches)

These are not all of the possible side effects of NEMLUVIO.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information.